• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Tyra Biosciences Inc.

    4/18/25 3:27:10 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TYRA alert in real time by email
    DEFA14A 1 d123954ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.  )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    Tyra Biosciences, Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     
     


    LOGO

    Tyra Biosciences, Inc. Annual Meeting of Stockholders Thursday, May 29, 2025 10:00 AM, Pacific Time The Annual Meeting will be held live via webcast—Please visit www.proxydocs.com/TYRA for more details. For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/TYRA To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before May 19, 2025. SEE REVERSE FOR FULL AGENDA Meeting Materials: Notice of Meeting, Proxy Statement and Annual Report on Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting to be held on May 29, 2025 For Stockholders of record as of April 4, 2025 To order paper materials, use one of the following methods. Internet: www.investorelections.com/TYRA Call: 1-866-648-8133 Email: [email protected] * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved


    LOGO

    THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1 AND 2 Tyra Biosciences, Inc. Annual Meeting of Stockholders PROPOSAL 1. To elect three directors to serve as Class I directors for a three-year term expiring at the 2028 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified. 1.01 Todd Harris, Ph.D. 1.02 Adele M. Gulfo 1.03 S. Michael Rothenberg, M.D., Ph.D. 2. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. 3. To transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment of the Annual Meeting.

    Get the next $TYRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TYRA

    DatePrice TargetRatingAnalyst
    5/21/2025$33.00Overweight
    Piper Sandler
    1/7/2025$28.00Buy
    UBS
    10/18/2024$22.00 → $31.00Neutral → Buy
    BofA Securities
    8/15/2024$33.00Overweight
    Piper Sandler
    12/15/2023$25.00 → $15.00Buy → Neutral
    BofA Securities
    6/30/2023$27.00Outperform
    Wedbush
    2/3/2023$17.00Outperform
    Oppenheimer
    6/23/2022$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $TYRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tyra Biosciences to Participate at Upcoming Investor Conferences

      CARLSBAD, Calif., May 12, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate in the following investor conferences: Bank of America Global Healthcare Conference, May 13-15, 2025Format: Fireside chat and one-on-one investor meetingsPresentation Date/Time: Tuesday, May 13, 2025, at 5:15 PM PTLocation: Las Vegas, NVJefferies Global Healthcare Conference, June 3-5, 2025Format: One-on-one investor meetingsLocation: New York, NYUBS Biotech 1x1 Symposium, June 24,

      5/12/25 4:05:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights

      - BEACH301 study of TYRA-300 for Pediatric Achondroplasia (ACH) Open for Enrollment - - Initiated patient dosing in SURF431 study of TYRA-430 for hepatocellular carcinoma (HCC) - - Cash, cash equivalents, and marketable securities of $318.9 million at Q1 2025; runway through at least 2027 - CARLSBAD, Calif., May 8, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent corporate progress. "In 2025, we are focus

      5/8/25 4:05:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights

      - Three INDs cleared by US FDA for TYRA's proprietary precision small molecules - - TYRA-300 to be evaluated in three Phase 2 studies: SURF302 for Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC), BEACH301 for pediatric achondroplasia (ACH) and SURF301 for metastatic urothelial cancer (mUC) - - Cash, cash equivalents, and marketable securities of $341.4 million at YE 2024; runway through at least 2027 - CARLSBAD, Calif., March 27, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today rep

      3/27/25 4:05:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TYRA
    SEC Filings

    See more
    • SEC Form 8-K filed by Tyra Biosciences Inc.

      8-K - Tyra Biosciences, Inc. (0001863127) (Filer)

      5/29/25 4:22:58 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Tyra Biosciences Inc.

      EFFECT - Tyra Biosciences, Inc. (0001863127) (Filer)

      5/19/25 12:15:16 AM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Tyra Biosciences Inc.

      SCHEDULE 13G - Tyra Biosciences, Inc. (0001863127) (Subject)

      5/14/25 4:05:29 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TYRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler resumed coverage on Tyra Biosciences with a new price target

      Piper Sandler resumed coverage of Tyra Biosciences with a rating of Overweight and set a new price target of $33.00

      5/21/25 9:01:58 AM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Tyra Biosciences with a new price target

      UBS initiated coverage of Tyra Biosciences with a rating of Buy and set a new price target of $28.00

      1/7/25 8:31:57 AM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences upgraded by BofA Securities with a new price target

      BofA Securities upgraded Tyra Biosciences from Neutral to Buy and set a new price target of $31.00 from $22.00 previously

      10/18/24 7:41:59 AM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TYRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors

      CARLSBAD, Calif., Jan. 29, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today the appointment of Adele Gulfo to its Board of Directors. Ms. Gulfo brings nearly three decades of executive leadership experience to the TYRA board, with a strong track record in developing and commercializing some of the world's best-selling medicines at Pfizer, AstraZeneca, Viatris and Sumitomo Pharma. "Adele is one of the most accomplished drug developers in our industry, with nearly thirty years of global ex

      1/29/25 4:05:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

      -TYRA appoints urologic oncologist, Erik Goluboff, M.D., as SVP, Clinical Development to lead NMIBC- -First patient expected to be dosed in SURF302 in Q2 2025- CARLSBAD, Calif., Jan. 10, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for TYRA-300 allowing the company to proceed with a Phase 2 clinical trial of TYRA-300 in low-grade, intermediate risk non-muscle invasive bladder cance

      1/10/25 8:00:00 AM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights

      - Reported positive interim clinical proof-of-concept results for TYRA-300 in mUC from SURF301 Ph1/2 study - - IND cleared for Phase 2 study of TYRA-300 in pediatric achondroplasia (BEACH301) - - Strengthened leadership with appointment of Doug Warner, MD as Chief Medical Officer - - Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024 - CARLSBAD, Calif., Nov. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the quarter ended September 30

      11/7/24 4:05:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TYRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Harris Todd was granted 1,241 shares, increasing direct ownership by 0.09% to 1,357,168 units (SEC Form 4)

      4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

      3/18/25 6:44:12 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Fuhrman Alan was granted 1,238 shares, increasing direct ownership by 10% to 14,087 units (SEC Form 4)

      4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

      3/18/25 6:44:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kjellson Nina S sold $74,324 worth of shares (5,401 units at $13.76) (SEC Form 4)

      4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

      2/7/25 4:43:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TYRA
    Financials

    Live finance-specific insights

    See more
    • Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

      - Encouraging preliminary anti-tumor activity observed in heavily pre-treated population - - At ≥ 90 mg QD, 6 out of 11 (54.5%) patients with FGFR3+ mUC achieved a confirmed partial response (PR), with 100% disease control rate and sustained duration of activity - - Positive safety results across all QD doses, with infrequent FGFR2/FGFR1-associated toxicities - - Conference call scheduled for October 25th, 2024, at 8AM EDT - CARLSBAD, Calif., Oct. 24, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, ann

      10/24/24 6:21:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET

      CARLSBAD, Calif., Oct. 23, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast on October 25, 2024 at 8:00 am ET to share interim clinical results of TYRA-300 from the SURF301 Phase 1/2 study in metastatic urothelial cancer (mUC). These data will be presented in a late-breaking oral presentation at the 36th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, being held October 23-25, 2024, in Barcelona, Spain. Gary Ste

      10/23/24 4:05:00 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia

      - In preclinical models, TYRA-300 demonstrated significant increases in growth and bone length- -Phase 2 clinical study for pediatric achondroplasia planned to be initiated in 2024--Conference call and webcast today, March 1st, at 8:00 am ET- CARLSBAD, Calif., March 1, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptors (FGFR) biology, today announced that it is expanding development of TYRA-300 into achondroplasia (ACH) based on positive preclinical results demonstrated in a study performed in collaboration with the Ima

      3/1/23 7:00:00 AM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TYRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Tyra Biosciences Inc.

      SC 13D/A - Tyra Biosciences, Inc. (0001863127) (Subject)

      12/6/24 9:30:49 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Tyra Biosciences Inc.

      SC 13D/A - Tyra Biosciences, Inc. (0001863127) (Subject)

      11/19/24 9:31:34 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tyra Biosciences Inc.

      SC 13G/A - Tyra Biosciences, Inc. (0001863127) (Subject)

      11/14/24 5:47:01 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TYRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ra Capital Management, L.P. bought $19,836,066 worth of shares (1,220,681 units at $16.25) (SEC Form 4)

      4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

      11/13/24 5:00:07 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Fuhrman Alan bought $151,954 worth of shares (9,500 units at $16.00), increasing direct ownership by 284% to 12,849 units (SEC Form 4)

      4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

      11/1/24 4:22:45 PM ET
      $TYRA
      Biotechnology: Pharmaceutical Preparations
      Health Care